Purpose . The aim of the present study was to estimate the one-year prevalence and recovery rate of self-reported chemosensory dysfunction in a series of subjects with previous mild-to-moderate symptomatic COVID-19 . Methods Prospective study based on the SNOT-22 (item sense of smell or taste) and additional outcomes . Results 268/315 patients (85.1 %) completing the survey at baseline also completed the follow-up interview . The 12-months prevalence of self-reported COVID-19 associated chemosensory dysfunction was 21.3% (95% CI : 16.5-26.7 %). Of the 187 patients who complained of COVID-19 associated chemosensory dysfunction at baseline , 130 (69.5% ; 95% CI 62.4-76.0 %) reported complete resolution of smell or taste impairment, 41 (21.9 %) reported a decrease in the severity, and 16 (8.6 %) reported the symptom was unchanged or worse one year after onset . The risk of persistence was higher for patients reporting a baseline SNOT-22 score> o = 4 (OR=3.32; 95% CI : 1.32-8.36) as well as for those requiring> o = 22 days for a negative swab (OR=2.18; 95% CI : 1.12-4.27). Conclusion A substantial proportion of patients with previous mild-to-moderate symptomatic COVID-19 characterized by new onset of chemosensory dysfunction still complained on altered sense of smell or taste one-year after the onset.